The commercial oral tablet strength of avatrombopag is 20 mg. Direct compression is evaluated first because it avoids heat and moisture, but the formulation cannot be treated as a simple low-dose blend: a 20 mg dose in a 100 mg core is 20% w/w API, and in a 200 mg core it remains 10% w/w. The API-rich fraction therefore influences powder flow, tensile strength, and segregation more than an excipient-like drug load would. A pre-blend is screened through a 600 μm stainless-steel mesh to break soft agglomerates, then charged into a bin blender with microcrystalline cellulose and lactose monohydrate at a fill volume not exceeding 70% of gross capacity. Colloidal silicon dioxide at 0.2–0.5% w/w can be added as a glidant. Magnesium stearate is screened through a 250 μm mesh and added at 0.5% w/w for 3 min of lubrication; longer mixing can reduce compactibility. Tableting is carried out on a rotary press with 8 mm standard concave tooling, with compression force monitored between 5 kN and 15 kN. Crushing strength and friability are measured with a hardness tester and a friabilator run at 100 revolutions; the friability limit is not more than 1.0% w/w per USP <1216>. Content uniformity follows USP <905> or Ph. Eur. 2.9.40, and in-process blend uniformity is controlled under 21 CFR 211.110. Dissolution is performed by USP <711> in media justified by pH-solubility profiling. Because the compound has low aqueous solubility, particle size is a critical variable: a screening acceptance limit of D90 ≤ 20 μm by laser diffraction per USP <429> is commonly used for poorly soluble small molecules, but no avatrombopag-specific compendial particle-size specification is published. The finished cores may be film-coated in a perforated pan using a polyvinyl alcohol-based coating dispersion at a weight gain of 3% w/w, with inlet air temperature 60–70°C and exhaust temperature 40–50°C. The pharmaceutical-grade API used for direct compression must meet ICH Q7 GMP requirements, ICH Q3C residual solvent limits, and ICH Q3D elemental impurity limits before tableting.

Wet Granulation Offers a Route Around Poor Compactibility and Segregation

When direct compression shows capping at compression speeds above 40 rpm or API-rich fines migrate in the hopper, high-shear wet granulation is the standard next step. Avatrombopag is processed with a binder solution made from povidone K30 or hypromellose E5 dissolved in purified water; binder concentration from 3% w/w to 5% w/w of dry granulation mass is typical, but the exact ratio must be adjusted to the surface area of the micronized API. The dry blend containing lactose monohydrate, microcrystalline cellulose, and croscarmellose sodium is mixed in a high-shear granulator at impeller speed 250–400 rpm and chopper speed 1500–3000 rpm. Purified water is added by peristaltic pump at 20–30 g/min per kg of dry mass, and wet massing continues for 120–180 s. Water addition above 30% w/w of dry mass can produce coarse, overwet agglomerates that later dry into hard granules with poor compressibility. The wet mass is transferred to a fluid-bed dryer with inlet air at 60–70°C and dried until loss on drying is below 2.0% w/w by USP <731>. Dried granules are milled through a 1.0 mm screen, and extragranular disintegrant croscarmellose sodium at 2.0% w/w plus magnesium stearate at 0.5% w/w are added. Granule size distribution is measured by sieve analysis according to USP <786>. The main regulatory controls are 21 CFR 211.110 in-process blend uniformity, USP <905> content uniformity, and USP <711> dissolution. Granulation reduces segregation and improves compactibility, but it introduces a moisture and heat history; forced degradation under ICH Q1A conditions must confirm that the API remains stable after wet massing and drying. The terminal product is a film-coated tablet with reproducible hardness, low friability, and a dissolution profile controlled by granule porosity and disintegrant distribution.

When moisture exposure must be minimized, roller compaction provides a solvent-free granulation route. A blend of avatrombopag, microcrystalline cellulose, and pregelatinized starch is compacted between counter-rotating rolls at a hydraulic pressure of 3–8 kN/cm. The resulting ribbons are milled with a low-shear granulator fitted with a 0.8 mm screen, and the granules are lubricated with 0.5% w/w sodium stearyl fumarate. This route avoids the hydrolytic risk of wet massing but can produce a less compressible granule; final tablet hardness and disintegration are therefore confirmed per USP <701> and USP <1216>.

Can Capsule Filling Maintain Content Uniformity Without Granulation?

Capsule filling of a 20 mg dose in size 0 or size 1 shells is technically feasible only if the API-rich fraction is kept fine and well dispersed. Direct powder filling on a tamping-pin encapsulator can achieve fill weight RSD below 3%, but the flow of a blend containing micronized avatrombopag is often poor without a granulation step. If a dry blend is used, lactose monohydrate or dicalcium phosphate dihydrate is selected as the main filler, and a glidant such as colloidal silicon dioxide at 0.2–0.5% w/w is blended before the lubricant. Capsule shell moisture influences the physical state of the powder plug: gelatin shells typically contain 13–16% w/w water, while HPMC shells contain 4–6% w/w water; low-moisture HPMC shells are preferred if the API is moisture-sensitive. Powder plug hardness and disintegration are measured indirectly by dissolution testing in USP Apparatus I or II, but the capsule shell itself must first comply with USP <701> disintegration. Content uniformity of filled capsules follows USP <905> or Ph. Eur. 2.9.40. Weight sorting is performed on an automatic check weigher with rejection limits set at ± 5.0% of target fill weight. If tamping pin compression causes the API to remain aggregated inside the plug, dissolution lag can occur; a disintegration test alone may not detect this, so dissolution of the capsule must be compared with the approved tablet at the same pH and surfactant concentration to establish equivalence. The terminal product is a hard capsule containing a dry powder or granulated fill, with the capsule shell selected according to moisture protection, machinability on the filling line, and patient swallowability.

For patients requiring a suspension, granules can be filled into sachet packs and reconstituted before administration. The formulation challenge is not tableting but suspension homogeneity and palatability. Avatrombopag is poorly water-soluble, so the granules must contain a wetting agent such as polysorbate 80 at 0.5–1.0% w/w and a suspending agent such as xanthan gum at 0.2% w/w or microcrystalline cellulose/sodium carboxymethylcellulose at 2.0% w/w. The reconstitution volume is adjusted to 30–50 mL, and the dose is withdrawn using an oral dosing syringe. Sedimentation ratio is measured after 30 s and 60 s; the top and bottom samples are assayed by HPLC and should not differ by more than 5.0% relative. Moisture content of the granules is controlled by USP <731> with a limit not exceeding 2.0% w/w, and microbial limits follow USP <61> and USP <62>. The common failure on production scale is inconsistent sachet fill weight because granule flow declines after storage at relative humidity above 60%; this is managed by adding colloidal silicon dioxide and by sealing sachets with an aluminum foil laminate barrier structure. A preservative is not included in single-dose sachets; the reconstituted suspension must be used immediately unless supported by in-use stability data. The terminal product is a single-dose sachet containing dispersible granules that form a suspension when mixed with water.

When a Lyophilized Injectable Presentation Is Required, Solubility Constraints Govern the Formulation Route

Injectable avatrombopag would require an aqueous solubility strategy because the free base has low water solubility. No approved injectable avatrombopag formulation is currently established, so published avatrombopag-specific injectable stability and solubility data are limited. A conventional approach for a poorly soluble weak base is pH adjustment into the acidic range, but pH values below 2.5 can accelerate hydrolysis and produce pain on injection. Cosolvents such as PEG 400 at 20–40% v/v and propylene glycol at 20–30% v/v may be combined with a surfactant such as polysorbate 80 at 0.1–0.5% w/v, but the final pH, osmolality, and hemolytic potential must be measured against USP <785> osmolality and the in-vitro hemolysis ratio. Sulfobutylether-β-cyclodextrin at 20–40% w/v can raise apparent solubility by inclusion-complex formation; the complexation efficiency must be confirmed by phase-solubility analysis, not assumed from structurally similar drugs. For lyophilized cakes, the bulk solution is filled into Type I glass vials, partially stoppered with bromobutyl closures, and frozen on shelf at −40°C to −50°C. Primary drying is run at a chamber pressure of 100–200 mTorr with shelf temperature from −20°C to −10°C; secondary drying at 25–35°C reduces residual moisture to below 1.0% w/w. Cake appearance is inspected, and reconstitution time is measured with a 20 mL diluent volume; a cake that reconstitutes in more than 2 min may indicate over-drying or insufficient bulking agent. Mannitol at 2–4% w/v or glycine at 1–2% w/v is used as bulking agent, but mannitol can crystallize during freezing and glycine can lower collapse temperature; the actual formulation must be optimized by freeze-drying microscopy. The finished injectable is tested for sterility by USP <71>, bacterial endotoxins by USP <85>, particulate matter by USP <788>, and sub-visible particles by USP <787> if a protein or biologic is present; avatrombopag is a small molecule so USP <788> is the primary particle standard. Container closure integrity is validated by dye ingress or vacuum decay according to USP <1207>.

Injectable Emulsion and Micellar Solubilisation Feasibility

For a highly lipophilic molecule, sterile oil-in-water emulsions and micellar concentrates may be screened as alternative injectable presentations. A typical screening emulsion base contains purified soybean oil 10% w/v, purified egg phospholipid 1.2% w/v, and glycerol 2.25% w/v; the active compound is dissolved in the oil phase at 60–70°C before high-shear mixing with the aqueous phase. The coarse emulsion is passed through a microfluidizer at 500–1000 bar until the mean droplet diameter is below 500 nm by dynamic light scattering per ISO 22412. The final emulsion is autoclaved at 121°C for 15 min if the drug substance has an acceptable thermal stability profile; if not, sterile filtration through a 0.22 μm membrane can be used only when the droplet size distribution shows no significant population above 220 nm. Micellar systems based on polysorbate 80 and PEG-15 hydroxystearate may be lower viscosity but carry higher local irritation potential. No avatrombopag-specific injectable emulsion data are available in the public domain; such formulations are experimental and require full toxicology, sterility, and particulate matter characterization. Testing includes droplet size by ISO 22412, zeta potential by electrophoretic light scattering, osmolality by USP <785>, bacterial endotoxin by USP <85>, and particulate matter by USP <788>.